4ZFC

Crystal structure of AKR1C3 complexed with glicazide

Summary for 4ZFC

• Entry DOI: 10.2210/pdb4zfc/pdb
• Descriptor: Aldo-keto reductase family 1 member C3, NADP NICOTINAMIDE-ADENINE-DINUCLEOTIDE PHOSPHATE, N-[(3aR,6aS)-hexahydrocyclopenta[c]pyrrol-2(1H)-ylcarbamoyl]-4-methylbenzenesulfonamide, ... (4 entities in total)
• Functional Keywords: akr1c3 inhibitor, oxidoreductase-oxidoreductase inhibitor complex, oxidoreductase/oxidoreductase inhibitor
• Biological source: Homo sapiens (Human)
• Cellular location: Cytoplasm: P42330
• Total number of polymer chains: 2
• Total formula weight: 75946.09

Authors

Zhao, Y.,Zhrng, X.,Hu, X. (deposition date: 2015-04-21, release date: 2015-11-25, Last modification date: 2024-03-20)

Primary citation

Zhao, Y.,Zheng, X.,Zhang, H.,Zhai, J.,Zhang, L.,Li, C.,Zeng, K.,Chen, Y.,Li, Q.,Hu, X.
In vitro inhibition of AKR1Cs by sulphonylureas and the structural basis
Chem.Biol.Interact., 240:310-315, 2015

PubMed Abstract: Recent epidemiological studies show conflicting data for the first-line anti-diabetic sulphonylureas drugs in treating cancer progression in type II diabetes patients. How sulphonylureas promote or diminish tumor growth is not fully understood. Here, we report that seven sulphonylureas exhibit different in vitro inhibition towards AKR1Cs (AKR1C1, AKR1C2, AKR1C3), which are critical steroid hormone metabolism enzymes that are related to prostate cancer, breast cancer and endometrial diseases. Interactions of the sulphonylureas and AKR1Cs were analyzed by X-ray crystallography.

PubMed: 26362498
DOI: 10.1016/j.cbi.2015.09.006

Experimental method

X-RAY DIFFRACTION (2 Å)